• Policy
• Billions of won in losses if applied retroactively
• by Lee, Tak-Sun Jul 22, 2022 05:53am

• Company
• Takeda's anti-cancer drug Exkivity has been approved
• by Jul 22, 2022 05:53am

• Policy
• Negotiations for Pfizer Lorviqua have not been completed
• by Lee, Tak-Sun Jul 22, 2022 05:52am

• Company
• Imbruvica makes 4th attempt to extend reimbursement
• by Eo, Yun-Ho Jul 21, 2022 06:04am

• Policy
• “Pharma companies cannot conduct online product briefings"
• by Kim, Jung-Ju Jul 21, 2022 06:04am

• Company
• Tabrecta is scheduled to be introduced in August
• by Eo, Yun-Ho Jul 20, 2022 05:50am

• Policy
• Companies receive mixed reimb results in urothelial cancer
• by Lee, Tak-Sun Jul 20, 2022 05:49am

• Company
• Moderna to soon release bivalent COVID-19 vaccine
• by Jul 20, 2022 05:49am

• Policy
• The age group for SKYCovione was expanded
• by Lee, Jeong-Hwan Jul 20, 2022 05:49am

• Policy
• Lipilouzet, which is more expensive than Atozet
• by Lee, Tak-Sun Jul 20, 2022 05:49am